Annals of Surgical Oncology最新文献

{"title":"Risk of Malignancy for Indeterminate Cytology of Bile Duct Strictures: A Systematic Review and Meta-analysis.","authors":"Kayla R Lieb, Zachary E Williams, Harlan Sayles, Muizz Zaman, Mashaal Dhir","doi":"10.1245/s10434-025-17292-y","DOIUrl":"10.1245/s10434-025-17292-y","url":null,"abstract":"<p><strong>Background: </strong>Malignancy remains one of the major differentials for bile duct strictures (BDS). Endoscopic sampling of the BDS provides low and variable sensitivity, often reporting \"atypical\" or \"suspicious\" cytology results in accordance with Papanicolaou criteria. We sought to perform a systematic review investigating the risk of malignancy for initially indeterminate cytology to aid in preoperative patient counseling.</p><p><strong>Patients and methods: </strong>A comprehensive search of databases including Scopus, EMBASE, and PubMed, was performed between each database's inception and 8 July 2024. Observational studies confirming malignancy rates in patients with atypical and/or suspicious bile duct cytology upon initial endoscopic brush cytology were included. Two reviewers independently screened articles and extracted data. Of 4159 articles initially identified, 144 were examined in full-text review and 46 were deemed eligible for inclusion.</p><p><strong>Results: </strong>Of 8458 total samples, 2826 (33.3%) samples had indeterminate brush cytology, consisting of either atypical (n = 1902) or suspicious (n = 924) brushings. Malignancy risk in samples with atypical and suspicious brush cytology was 50.4% and 80.2%, respectively. Suspicious cytology was associated with a relative risk of 1.59 for malignancy relative to atypical cytology. There was a 60.1% risk of malignancy among all samples with indeterminate brush cytology.</p><p><strong>Conclusions: </strong>Our study provides pooled estimates of risk of malignancy in patients with bile duct strictures and indeterminate cytology. This is one of the first meta-analyses on the topic. Our findings can be used by physicians for preoperative counseling of patients being worked up surgically for biliary strictures with indeterminate cytology.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5657-5666"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a Rabbit Model of Peritoneal Metastases: PIPALIM Project.","authors":"Sylvia M Bardet, Marie-Laure Perrin, Valentin David, Catherine Yardin, Alain Chaunavel, Karine Durand, Gaelle Maillan, Aymeric Rouchaud, Sylvaine Durand Fontanier, Abdelkader Taibi","doi":"10.1245/s10434-025-17251-7","DOIUrl":"10.1245/s10434-025-17251-7","url":null,"abstract":"<p><strong>Background: </strong>Animal models are essential for testing new pressurized intraperitoneal aerosol chemotherapy (PIPAC) protocols; however, no immunocompetent animal model of peritoneal surface malignancies (PSMs) treated with PIPAC has been established. This study evaluated the feasibility, safety, and oncological efficacy of PIPAC in a rabbit PSM model.</p><p><strong>Methods: </strong>The study was conducted in two phases: (1) Feasibility Assessment: Three healthy rabbits underwent three consecutive PIPAC procedures (saline) at weekly intervals. The rabbits' well-being, morbidity, mortality, and histological changes were monitored. (2) Treatment Phase: Rabbits with PSM were treated with PIPAC using oxaliplatin, cisplatin-doxorubicin, or saline. Parameters such as animal well-being, ascites volume, morbidity, Peritoneal Cancer Index (PCI), histological response (Peritoneal Regression Grading Score [PRGS]), tumor cell proliferation/apoptosis, and circulating tumor DNA (ctDNA) levels were assessed.</p><p><strong>Results: </strong>PIPAC was feasible and safe, with no increased morbidity or mortality. PIPAC demonstrated antitumor efficacy with lower PCI (control 21.6 vs. oxaliplatin 9.2 vs. cisplatin-doxorubicin 10.2; p < 0.001), improved histological response (PRGS: control 3.38 vs. oxaliplatin 1.95 vs. cisplatin-doxorubicin 1.85; p = 0.01), and reduced tumor cell proliferation (control 5.3% vs. oxaliplatin 0.82% vs. cisplatin-doxorubicin 0.62%; p < 0.0001). ctDNA levels showed promise for monitoring treatment response, warranting further investigation.</p><p><strong>Conclusion: </strong>This study confirms the feasibility and effectiveness of PIPAC with oxaliplatin or cisplatin-doxorubicin in rabbits with PSM. The model provides a foundation for future research on PIPAC protocols and related treatments.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"6050-6057"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Overview of the Importance of Neoadjuvant Systemic Therapy for Breast Cancer Patients: From the Society of Surgical Oncology and the American Society of Breast Surgeons.","authors":"Anna Weiss, Doreen M Agnese, Zahraa Al-Hilli, Neslihan Cabioglu, Deborah Farr, Olga Kantor, Samilia Obeng-Gyasi, Lee Wilke","doi":"10.1245/s10434-025-17405-7","DOIUrl":"10.1245/s10434-025-17405-7","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5453-5466"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Artificial Intelligence for Precision Diagnosis and Treatment of Bladder Cancer: A Review.","authors":"Xiangxiang Yang, Rui Yang, Xiuheng Liu, Zhiyuan Chen, Qingyuan Zheng","doi":"10.1245/s10434-025-17228-6","DOIUrl":"10.1245/s10434-025-17228-6","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is one of the top ten cancers globally, with its incidence steadily rising in China. Early detection and prognosis risk assessment play a crucial role in guiding subsequent treatment decisions for bladder cancer. However, traditional diagnostic methods such as bladder endoscopy, imaging, or pathology examinations heavily rely on the clinical expertise and experience of clinicians, exhibiting subjectivity and poor reproducibility.</p><p><strong>Materials and methods: </strong>With the rise of artificial intelligence, novel approaches, particularly those employing deep learning technology, have shown significant advancements in clinical tasks related to bladder cancer, including tumor detection, molecular subtyping identification, tumor staging and grading, prognosis prediction, and recurrence assessment.</p><p><strong>Results: </strong>Artificial intelligence, with its robust data mining capabilities, enhances diagnostic efficiency and reproducibility when assisting clinicians in decision-making, thereby reducing the risks of misdiagnosis and underdiagnosis. This not only helps alleviate the current challenges of talent shortages and uneven distribution of medical resources but also fosters the development of precision medicine.</p><p><strong>Conclusions: </strong>This study provides a comprehensive review of the latest research advances and prospects of artificial intelligence technology in the precise diagnosis and treatment of bladder cancer.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"6173-6184"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Recurrence-Free Survival Prediction in Hepatocellular Carcinoma: A Time-Updated Model Incorporating Tumor Burden and AFP Dynamics.","authors":"Miho Akabane, Jun Kawashima, Abdullah Altaf, Selamawit Woldesenbet, François Cauchy, Federico Aucejo, Irinel Popescu, Minoru Kitago, Guillaume Martel, Francesca Ratti, Luca Aldrighetti, George A Poultsides, Yuki Imaoka, Andrea Ruzzenente, Itaru Endo, Ana Gleisner, Hugo P Marques, Sara Oliveira, Jorge Balaia, Vincent Lam, Tom Hugh, Nazim Bhimani, Feng Shen, Timothy M Pawlik","doi":"10.1245/s10434-025-17303-y","DOIUrl":"10.1245/s10434-025-17303-y","url":null,"abstract":"<p><strong>Background: </strong>Existing models to predict recurrence-free survival (RFS) after hepatectomy for hepatocellular carcinoma (HCC) rely on static preoperative factors such as alpha-fetoprotein (AFP) and tumor burden score (TBS). These models overlook dynamic postoperative AFP changes, which may reflect evolving recurrence risk. We sought to develop a dynamic, real-time model integrating time-updated AFP values with TBS for improved recurrence prediction.</p><p><strong>Patients and methods: </strong>Patients undergoing curative-intent hepatectomy for HCC (2000-2023) were identified from an international, multi-institutional database with RFS as the primary outcome. AFP trajectory was monitored from preoperative to 6- and 12-month postoperative values, using time-varying Cox regression with AFP as a time-dependent covariate. The predictive accuracy of this time-updated model was compared with a static preoperative Cox model excluding postoperative AFP.</p><p><strong>Results: </strong>Among 1911 patients, AFP trajectories differed between recurrent and nonrecurrent cases. While preoperative AFP values were similar, recurrent cases exhibited higher AFP at 6 and 12 months. Multivariable analysis identified TBS (hazard ratio (HR):1.043 [95% confidence interval (CI): 1.002-1.086]; p = 0.039) and postoperative log AFP dynamics (HR:1.216 [CI 1.132-1.305]; p < 0.001) as predictors. Contour plots depicted TBS's influence decreasing over time, while postoperative AFP became more predictive. The time-varying Cox model was created to update RFS predictions continuously on the basis of the latest AFP values. The preoperative Cox model, developed with age, AFP, TBS, and albumin-bilirubin score, had a baseline C-index of 0.61 [0.59-0.63]. At 6 months, the time-varying model's C-index was 0.70 [0.67-0.73] versus 0.59 [0.56-0.61] for the static model; at 12 months, it was 0.70 [0.66-0.73] versus 0.56 [0.53-0.59]. The model was made available online ( https://nm49jf-miho-akabane.shinyapps.io/AFPHCC/ ).</p><p><strong>Conclusions: </strong>Incorporating postoperative AFP dynamics into RFS prediction after HCC resection enhanced prediction accuracy over time, as TBS's influence decreased. This adaptive, time-varying model provides refined RFS predictions throughout follow-up.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5648-5656"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative Radiation Therapy (IORT) for Breast Cancer: The Final Analysis of a Prospective Cohort of 1828 Cases.","authors":"Melvin J Silverstein, Brian Kim, Kevin Lin, Shane Lloyd, Lincoln Snyder, Sadia Khan, Deena Hossino, Peter Chen","doi":"10.1245/s10434-025-17546-9","DOIUrl":"10.1245/s10434-025-17546-9","url":null,"abstract":"<p><strong>Background: </strong>Intraoperative radiation therapy (IORT) delivers the full course of radiation therapy during the initial surgical excision. In the early 2000s, IORT was a promising method of breast cancer treatment de-escalation, offering many advantages. This technique should have succeeded in the USA, but several factors hindered its widespread adoption. We report the results of our 15-year IORT registry trial and our reasons for halting the trial.</p><p><strong>Patients and methods: </strong>Patients with early-stage breast cancer were entered into an institutional review board (IRB) approved registry. They were analyzed by intention to treat and by various subgroups, including those who received local treatment to the area of the primary tumor only versus those who received additional whole breast treatment.</p><p><strong>Results: </strong>A total of 1785 patients with 1828 early-stage breast cancers entered the registry. With a median follow-up of 85 months, the local recurrence rate (LRR) at 5-years for the entire cohort was 4.44%. Among 1527 who received local treatment only, the LRR at 5-years was 5.09% compared with 1.13% for 301 patients who received additional whole breast treatment (p = 0.001). For patients aged ≥ 65 with luminal A tumors ≤ 20mm, the 5-year LRR dropped to 2.32%.</p><p><strong>Conclusions: </strong>IORT is extremely convenient for the patient and offers many advantages when compared with other methods of partial or whole breast treatment. Overall, the LRR for IORT is 4-5 times higher than many competing forms of whole or accelerated partial breast irradiation but still relatively low. A more select choice of patients for IORT can lower the LRR. Following the decision by ASTRO in 2024 not to recommend IORT, and considering a number of other factors, our group made the decision to discontinue our IORT program.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5563-5571"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the Management of Small HER2-Positive Breast Cancers.","authors":"Carolin Mueller, Rahul Rangan, Megan Kruse, Zahraa Al-Hilli","doi":"10.1245/s10434-025-17430-6","DOIUrl":"10.1245/s10434-025-17430-6","url":null,"abstract":"<p><strong>Background: </strong>The treatment approach for small HER2-positive (+) breast cancers seeks to optimize efficacy while minimizing potential overtreatment and associated toxicities. This study aims to evaluate recent trends in treatment patterns for small HER2+ tumors.</p><p><strong>Methods: </strong>Patients diagnosed with HER2+, cT1, cN0/pN0 breast cancer treated at a single institution from January 2018 to December 2022 were included. Clinicopathological, treatment, and follow-up data were collected and analyzed.</p><p><strong>Patients and results: </strong>A total of 207 patients were included. Mean age was 63 (± 12.0) years. T category included cT1a in 12.1% (n = 25), cT1b in 28.0% (n = 58), and cT1c in 57.5% (n = 119), while 2.4% (n = 5) had clinical T1 category without further specification. Moreover, 74.4% (n = 154) were hormone receptor positive. Also, 66.7% (n = 138) received adjuvant therapy, 12.6% (n = 26) received neoadjuvant systemic therapy (NAT), and 12.1% (n = 25) received no systemic therapy. Administered regimens included: trastuzumab monotherapy in 6.1% (n = 10), taxane/trastuzumab in 55.5% (n = 91), taxane/carboplatin/trastuzumab in 18.9% (n = 31), and taxane/carboplatin/trastuzumab/pertuzumab in 15.2% (n = 25). In the 26 patients who received NAT, pathological complete response (pCR) was noted in 69.2% (n = 18). Overall, use of NAT increased from 2018 (7.1%) to 2021 (30.2%) and then decreased in 2022 (9.1%). The overall mastectomy rate was 35.3% (n = 73). Young age and multiple tumors were associated with a higher rate of mastectomy (age p < 0.001; multiple tumors p = 0.006). Upstaging of clinically node-negative patients occurred in 14.1% of patients at surgery.</p><p><strong>Conclusion: </strong>The treatment for cT1N0 HER2+ breast cancers includes primary surgery with adjuvant HER2-targeted therapy in combination with chemotherapy. Primary surgery may allow for an opportunity to deescalate adjuvant therapy with no impact on surgical plan.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5510-5520"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Approaches to High-Risk Anastomoses in Robotic Pancreatoduodenectomy.","authors":"Francesca Marcucci, Giovanna Carillo, Patricia Sánchez-Velázquez, Alberto Garcia-Picazo, Fernando Burdio, Benedetto Ielpo","doi":"10.1245/s10434-025-17402-w","DOIUrl":"10.1245/s10434-025-17402-w","url":null,"abstract":"<p><strong>Background: </strong>Pancreatoduodenectomy (PD) is performed for the treatment of pancreatic head and periampullary tumors and is associated with relatively high postoperative morbidity and mortality. Traditionally conducted as open surgery, PD has evolved with the advent of minimally invasive techniques, including robotic-assisted approaches.</p><p><strong>Results: </strong>As reported in the literature, minimally invasive PD is becoming a safe and effective alternative surgical approach. Clinically relevant postoperative pancreatic complications, such as fistulas and hemorrhage, remain among the most challenging issues after PD, particularly in high-risk cases. There are several maneuvers that may reduce their incidence and mitigate their postoperative clinical impact.</p><p><strong>Conclusions: </strong>In this video, we describe strategies implemented at our center for high-risk PD cases, including some key tips and tricks.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5717-5719"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low TIF1γ Expression is Associated with Cancer Aggressiveness and Shorter Recurrence-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.","authors":"Arisa Yamaguchi, Takehiko Yokobori, Makoto Sohda, Takayoshi Watanabe, Nobuhiro Nakazawa, Akihiko Sano, Makoto Sakai, Takuya Shiraishi, Sei-Ichiro Motegi, Ken Shirabe, Hiroshi Saeki","doi":"10.1245/s10434-025-17238-4","DOIUrl":"10.1245/s10434-025-17238-4","url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) is a significant cause of cancer-related death despite advances in multidisciplinary treatment. Transcriptional intermediary factor 1 γ (TIF1γ) has been known to be involved in tumorigenesis and epithelial-mesenchymal transition (EMT), which are linked to cancer aggressiveness and therapeutic resistance. However, its role in ESCC remains unclear. Therefore, we investigated the expression significance and function of TIF1γ in ESCC.</p><p><strong>Methods: </strong>We used immunohistochemical analysis to investigate the clinical significance of tumoral TIF1γ expression in 131 patients with ESCC. We also performed in vitro analysis using ESCC cell lines to evaluate the effects of TIF1γ suppression on EMT marker expression, migration ability, and 5-fluorouracil (5-FU) sensitivity.</p><p><strong>Results: </strong>The TIF1γ protein was mainly expressed in the nuclear ESCC cells. Low nuclear TIF1γ expression was associated with the progression of tumor depth and frequent recurrence. Low TIF1γ expression was an independent predictor of recurrence in ESCC. Moreover, suppression of TIF1γ facilitated EMT-like changes, such as high migration ability, E-cadherin suppression, vimentin induction, and 5-FU resistance of ESCC cells.</p><p><strong>Conclusions: </strong>TIF1γ may be a promising biomarker for predicting patients with ESCC at high risk of recurrence. Therapeutic strategies that induce TIF1γ expression are expected to improve the chemosensitivity and prognosis of high-risk patients with ESCC who have low TIF1γ.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"6023-6030"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Urological Cancers in the Labour Force from 1990 to 2021 and Projections to 2050.","authors":"Junyan Chen, Cen Meng","doi":"10.1245/s10434-025-17234-8","DOIUrl":"10.1245/s10434-025-17234-8","url":null,"abstract":"<p><strong>Background: </strong>Urological cancers represent an increasing public health concern in the labour force, mainly including prostate cancer (PCA), kidney cancer (KCA), testicular cancer (TCA), and bladder cancer (BLCA). Limited data exist on their occurrence, deaths, and disability-adjusted life years (DALYs). The objective of this study was to analyse three-decade trends in these cancers globally and forecast future patterns.</p><p><strong>Methods: </strong>The study used Global Burden of Disease 2021 data from 1990 to 2021 to evaluate urological cancer stats, including prevalence, incidence, mortality, and DALYs. For people aged 15-64 years, it was then manually age-standardized once. Herein, we employed a range of analytical techniques, including decomposition analysis, a Bayesian Age-Period-Cohort model, a Concentration index and slope index, and frontier analysis, to examine the trends in 204 countries and regions. Furthermore, the relationship between the Socio-Demographic Index (SDI) and the burden of disease is addressed.</p><p><strong>Results: </strong>Over the past 30 years, PCA, TCA, and KCA rates have risen among the global labour force population. North America, North Asia, and Europe have high incidence and mortality rates. TCA mortality and BLCA and TCA prevalence are expected to continue rising globally until 2050. Urological cancer impacts vary by region and development with more burden in areas with a higher SDI.</p><p><strong>Conclusions: </strong>Urological cancers represent a substantial disease burden on labour force populations, emphasizing the imperative for targeted interventions and healthcare resources for affected populations. It is therefore crucial to have a comprehensive understanding of the global and regional epidemiological trends, as well as the findings of health economics studies.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"6158-6172"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}